Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20_CUPIC study
ContributorsAbout, Frédégonde; Oudot-Mellakh, Tiphaine; Niay, Jonathan; Rabiéga, Pascaline; Pedergnana, Vincent; Duffy, Darragh; Sultanik, Philippe; Cagnot, Carole; Carrat, Fabrice; Marcellin, Patrick; Zoulim, Fabien; Larrey, Dominique; Hézode, Christophe; Fontaine, Hélène; Bronowicki, Jean-Pierre; Pol, Stanislas; Albert, Matthew L; Theodorou, Ioannis; Cobat, Aurélie; Abel, Laurent; ANRS CO20-CUPIC study group
CollaboratorsNegro, Francesco
Published inPLOS ONE, vol. 10, no. 12, e0145105
Publication date2015
Abstract
Keywords
- Anemia/complications
- Drug Therapy
- Combination
- Hemoglobins/metabolism
- Hepacivirus/physiology
- Hepatitis C
- Chronic/complications/drug therapy/genetics/virology
- Humans
- Interleukins/genetics
- Liver Cirrhosis/complications/drug therapy/genetics/virology
- Oligopeptides/adverse effects/therapeutic use
- Polymorphism
- Single Nucleotide/genetics
- Proline/adverse effects/analogs & derivatives/therapeutic use
- Pyrophosphatases/genetics
- Treatment Outcome
- Beta 2-Glycoprotein I/genetics
Affiliation
Research group
Citation (ISO format)
ABOUT, Frédégonde et al. Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20_CUPIC study. In: PLOS ONE, 2015, vol. 10, n° 12, p. e0145105. doi: 10.1371/journal.pone.0145105
Main files (1)
Article (Published version)
Identifiers
- PID : unige:126290
- DOI : 10.1371/journal.pone.0145105
- PMID : 26670100
ISSN of the journal1932-6203
